利伐沙班副作用及处理措施

Rivaroxaban, also known as Xarelto, is produced by Bayer Healthcare of Germany. It is a new type of oral anticoagulant with safe, effective, simple and intuitive anticoagulant effects. Therefore, in clinical practice, rivaroxaban has gradually replaced warfarin as the anticoagulant of choice for venous thrombosis, atrial fibrillation, pulmonary embolism and other diseases.

Rivaroxaban is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis. So, what are the side effects and treatment methods of using rivaroxaban?

The most common side effect of rivaroxaban is bleeding. Anticoagulant drugs all have a risk of bleeding, but the risk of clinical major bleeding is relatively low.

Secondly, some patients may also experience allergic reactions, such as urticaria, dermatitis, etc.

There are also some patients who may have a certain impact on liver and kidney function, causing an increase in creatinine and transaminases.

Some relatively rare side effects include abnormal blood vessels, abnormal number of platelets, changes in coagulation function, etc.

If the side effects are mild while taking rivaroxaban, you do not need targeted treatment. The side effects will gradually disappear as the medication time increases. If the side effects are severe or intolerable, please seek medical help in time.

Rivaroxaban drug interactions:

Concomitant use of rivaroxaban is not recommended in patients receiving systemic azole-antifungal agents (e.g., ketoconazole, itraconazole, voriconazole, and posaconazole) or HIV protease inhibitors (e.g., ritonavir). These active substances are potent inhibitors of CYP3A4 and P-gp and, therefore, may increase rivaroxaban plasma concentrations and cause a clinically relevant increase in the risk of bleeding.

Fluconazole is considered to have a small effect on rivaroxaban plasma concentrations and can be coadministered with caution. Use caution in patients receiving concomitant medications that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, platelet aggregation inhibitors, or other antithrombotic agents.